1 Min Read
Dec 18 (Reuters) - Beigene Ltd:
* BEIGENE INITIATES PIVOTAL TRIAL OF PARP INHIBITOR PAMIPARIB (BGB-290) IN CHINA IN PATIENTS WITH OVARIAN CANCER Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.